Medical News / ASH Meeting 2020, Vaccine Could Provide Long-Term Acute Myeloid Leukemia Remission

Preliminary findings from an ongoing assessment show an allogenic leukemia-derived dendritic cell vaccine is capable of generating tumor-specific immune responses as well as potential tumor control in patients with acute myeloid leukemia (AML). The data, presented this weekend at the American Society of Hematology (ASH) 2020 Annual Meeting, also presented 2 incidents in which patients were converted from measurable residual disease (MRD) positive to MRD negative status, with year-plus remission duration, after the vaccination. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

The modes of multiple myeloma assessment and screening has progressed over decades in near-alignment with the ... read more
A new study presented at the American Society of Hematology (ASH) 2020 Annual Meeting this weekend ... read more
A mobile health (mHealth) app may help children manage pain and symptoms related to sickle cell ... read more
Cognitive and emotional functions in pediatric patients should not be overlooked when assessing potential for sickle ... read more